Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
- 15 February 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (4), 1384-1392
- https://doi.org/10.1158/1078-0432.ccr-08-1615
Abstract
Purpose: The blood vessel-destabilizing Tie2 ligand angiopoietin-2 (Ang-2) acts in concert with the vascular endothelial growth factor/vascular endothelial growth factor receptor system to control vessel assembly during tumor progression. We hypothesized that circulating soluble Ang-2 (sAng-2) may be involved in melanoma progression. Experimental Design: Serum samples (n = 98) from melanoma patients (American Joint Committee on Cancer stages I-IV), biopsies of corresponding patients, and human melanoma cell lines were analyzed for expression of Ang-2 and S100β. Multiple sera of a subcohort of 33 patients were tested during progression from stage III to IV. Small interfering RNA-based loss-of-function experiments were done to assess effects of Ang-2 on melanoma cells. Results: Circulating levels of sAng-2 correlate with tumor progression in melanoma patients (P < 0.0001) and patient survival (P = 0.007). Analysis of serum samples during the transition from stage III to IV identified an increase of sAng-2 up to 400%. Comparative analyses revealed a 56% superiority of sAng-2 as predictive marker over the established marker S100β. Immunohistochemistry and reverse transcription-PCR confirmed the prominent expression of Ang-2 by tumor-associated endothelial cells but identified Ang-2 also as a secreted product of melanoma cells themselves. Corresponding cellular experiments revealed that human melanoma-isolated tumor cells were Tie2 positive and that Ang-2 acted as an autocrine regulator of melanoma cell migration and invasion. Conclusions: The experiments establish sAng-2 as a biomarker of melanoma progression and metastasis correlating with tumor load and overall survival. The identification of an autocrine angiopoietin/Tie loop controlling melanoma migration and invasion warrants further functional experiments and validate the angiopoietin/Tie system as a promising therapeutic target for human melanomas.Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- Angiopoietin‐2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2008
- Role of platelet-derived growth factors in physiology and medicineGenes & Development, 2008
- Reduced maternal serum concentrations of angiopoietin‐2 in the first trimester precede intrauterine growth restriction associated with placental insufficiencyBJOG: An International Journal of Obstetrics and Gynaecology, 2007
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Angiopoietin-2 is increased in severe sepsis: Correlation with inflammatory mediatorsCritical Care Medicine, 2007
- Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell traffickingJournal of Leukocyte Biology, 2006
- Semaphoring Vascular MorphogenesisEndothelium, 2006
- VEGF–VEGF receptor complexes as markers of tumor vascular endotheliumJournal of Controlled Release, 2001
- Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenograftsin vivoInternational Journal of Cancer, 2000
- Clinical significance of serum S100 in metastatic malignant melanomaEuropean Journal Of Cancer, 1995